|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Oral contraception with a new biphasic preparation. [Orale Kontrazeption |
| mit neuem Zweiphasenpraparat.] |
| Ars Medici. 1983;73(5):226-8. |
| In an open multicenter study, in which 50 gynecologists took part, a biphasic combination contraceptive was tested |
| in 440 women (2164 documented cycles). Binovum is a 21-day regimen containing ethinyl estradiol (EE) and |
| norethindrone (NE); the 1st 10 tablets contain 0.035 mg EE and 0.5 mg NE, the other 11 tablets contain 0.035 mg EE |
| and 1.0 mg NE. All women (age range 15-47 years) were tested for at least 6 cycles. Body weight remained within |
| normal physiological range througout the study. 60% registered 6 uninterrupted cycles. Spotting and/or breakthrough |
| bleeding decreased from 26.1% in the 1st cycle to 8% in the 2nd cycle; only 4.2% of the subjects registered spotting |
| after 6 cycles, 3.8% had breakthrough bleeding; i.e., 92% of all women had normal cycles. Average spotting rate was |
| 8.2%, breakthrough rate 8.1%. Withdrawal bleeding was 7% after 3 cycles, 3% after 6 cycles (average 6%). Side |
| effects such as breast tenderness, nausea, headache decreased from 21.8% (1st cycle) to 6.4% (6th cycle). |
| Tolerance was good to very good in 86.6%. 61.3% of the women were first-time pill users; others switched from one |
| agent to Binovum without pause. compares favorably with a triphasic preparation and with another combination |
| contraceptive containing a new kind of Progestin used in swedish studies. Side effects decrease with longer use. |
| NE has only a negligible effect on the endometrium (no postpill amenorrhea), has a favorable effect on acne, and has |
| no effect on HDL levels. All this points to the suitability of Binovum for initial adjustment to the pill or a changeover |
| from other agents. (PubHealth.info Document ID: CONT5T 2063-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Oral contraception with a new biphasic preparation. [Orale |
| Kontrazeption mit neuem Zweiphasenpraparat.]", is(are) Balmer J. The source of this article is "Ars Medici. |
| 1983;73(5):226-8.". This article was published in 1983 in German language(s). (PubHealth.info® Document ID: |
| CONT5T 2063-06. All rights reserved with PubHealth.info) PIN: 22063 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
